Recently, Elsevier Publishing Group and Stanford University released the list of world's top 2% scientists in 2024. This list is compiled by the team of Professor John P. A. Ioannidis from Stanford University and Mendeley Data Elsevier. The top 2% of leading scientists are selected from nearly 7 million scientists in 22 major fields and 176 minor areas. Dr. Huang has been selected for this list for five consecutive years since 2020, and his ranking has been rising year by year, with the actual rankings being 1.39%, 0.93%, 0.68%, 0.39%, and 0.26% globally from 2020 to 2024.

Dr. Li Haitao, CTO of Rigerna, said, “Dr. Huang‘s rising ranking fully demonstrates his outstanding global influence in oligonucleotide field. He has been deeply engaged in the field of nucleic acid drugs for 16+ years and is an outstanding scientist with enriched industrial experience. Under his leadership, Rigerna is committed and dedicated to becoming a transformative player in the siRNA sector. Our leading hepatic-targeting pipeline has entered the clinical stage recently. As for the extra-hepatic delivery, we have achieved significant milestones by Proof-of-Concept in non-human primates. We are confident about the future based on seasoned teams and innovative pipelines.”

Brief introduction of Dr. Huang Yuanyu, the founder of Rigerna:

Huang Yuanyu, Professors of Beijing Institute of Technology, has been focusing on the field of nucleic acid drug field for 16+ years and pioneering in extra-hepatic siRNA delivery sector. He has successfully brought 5 siRNA drugs into Phase I - II study. Dr. Huang has published more than 120 papers including Nat Rev Bioeng, Sci Adv, Nat Commun, STTT, Adv Mater, etc., and has applied for more than 40 patents, including 10 PCT patents.